Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Crohn's disease treated with new cost effective drugs

  • Comment

People suffering from severe Crohn’s disease could now be prescribed two alternative drugs if other commonly used treatments are not effective.

The National Institute for Health and Clinical Excellence (NICE) has approved infliximab and adalimumab for those whose condition cannot be treated with other therapies.

The drugs can be given to adults in whom the disease has taken a severe, active form, although cost must be considered and the cheaper drug administered first.

Adults with active, fistulising Crohn’s and children aged six to 17 with severe, active Crohn’s could be given infliximab, NICE recommended.

Dr Carole Longson, health technology evaluation centre director said: “We are pleased to recommend these treatments for this debilitating, incurable condition.

“Our review of the evidence indicates that infliximab and adalimumab are clinically and cost effective options for some people with the most severe forms of Crohn’s disease, and for those that standard treatments have failed, or are not an option”

The NHS will have to put the advice into practice within three months, to replace existing localised recommendations.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs